Cytokine signature in convalescent SARS-CoV-2 patients with inflammatory bowel disease receiving vedolizumab

Simone Dallari, Vicky Martinez Pazos, Juan Munoz Eusse, Judith Wellens, Craig Thompson, Jean Frederic Colombel, Jack Satsangi, Ken Cadwell, Serre Yu Wong, Jessica Anne Neil, Stela Sota, Kyung Ku Jang, Krystal Ching, Mericien Venzon, Xiaomin Yao, Lucie Bernard, Xin Chen, Michael Tankelevich, Reema Navalurkar, Rebekah DixonDrew S. Helmus, Marcia Mukanga Lange, Emily Spiera, Lodoe Sangmo

Research output: Contribution to journalArticlepeer-review

Abstract

While differential antibody responses SARS-CoV-2 in patients with inflammatory bowel disease (IBD) receiving infliximab and vedolizumab are well-characterized, the immune pathways underlying these differences remain unknown. Prior to COVID-19 vaccine development, we screened 235 patients with IBD receiving biological therapy for antibodies to SARS-CoV-2 and measured serum cytokines. In seropositive patients, we prospectively collected clinical data. We found a cytokine signature in patients receiving vedolizumab who are seropositive compared with seronegative for SARS-CoV-2 antibodies that may be linked to repeated SARS-CoV-2 infections. However, there were no differences between seropositive and seronegative patients receiving infliximab. In this single-center cohort of patients with IBD with anti-SARS-CoV-2 antibodies at the onset of the COVID-19 pandemic, and therefore without influence of vaccination, there is a cytokine signature in patients receiving vedolizumab but not infliximab. These findings lay the groundwork for further studies on immune consequences of viral infection in patients with IBD, which is postulated to evolve from aberrant host-microbe responses.

Original languageEnglish
Article number186
JournalScientific Reports
Volume14
Issue number1
DOIs
StatePublished - Dec 2024

Fingerprint

Dive into the research topics of 'Cytokine signature in convalescent SARS-CoV-2 patients with inflammatory bowel disease receiving vedolizumab'. Together they form a unique fingerprint.

Cite this